About Nxera Pharma

Nxera Pharma develops novel medicines using its proprietary NxWave platform, which applies structure-based drug design to GPCRs, historically challenging drug targets. The company focuses on neurology, metabolic disorders, immunology and rare diseases, advancing both in-house and partnered programmes from discovery through to commercialisation. Headquartered in Tokyo and publicly traded on the Tokyo Stock Exchange, Nxera operates R&D facilities in Cambridge, UK and commercial operations across Japan and South Korea. With marketed products already treating patients and a pipeline spanning early discovery to Phase 3, the company combines technology with regional expertise to deliver treatments to underserved populations.